Noventure grants Axmer exclusive distribution right for its products Oleoabrax® EHO and EPA3G® in Sweden, Denmark, Norway, Finland, Estonia, Latvia and Lithuania.
Oleoabrax® EHO is a hydrogel whose patented formulation grants it the ability to promote and speed up the process of healing wounds of full and partial thickness.
Oleoabrax® EHO is a class IIb medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL).
EPA3G® is a convenient IP-protected liquid emulsion that provides a more readily bioavailable formulation of EPA. Created using our unique Emugel™ omega-3 nano-emulsion technology, EPA3G® is the only product on the market offering a high quantity of almost 3g EPA in a single 20mL dosage form, thus helping to re-establish critical levels of omega-3 EPA.
EPA3G® is a food supplement.
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.